Rnai-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis b virus DNA is a source of hbsag

Science Translational Medicine

Volumn 9, Issue 409, 2017, Pages

  Wooddell, Christine I ^a   Yuen, Man Fung ^b   Chan, Henry Lik Yuen ^c   Gish, Robert G ^d   Locarnini, Stephen A ^e,f   Chavez, Deborah ^g   Ferrari, Carl ^h,i   Given, Bruce D ^a   Hamilton, James ^j   Kanner, Steven B ^a   Lai, Ching Lung ^b   Lau, Johnson Y N ^k   Schluep, Thomas ^j   Xu, Zhao ^a   Lanford, Robert E ^g   Lewis, David L ^a  

^a Bioanalysis Inc   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^f PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^g SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

^h UNIVERSITY OF PARMA   (Italy)

ⁱ UNIVERSITY HOSPITAL OF PARMA   (Italy)

^j Arrowhead Pharmaceuticals Inc   (United States)

^k HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ARC 520; COVALENTLY CLOSED CIRCULAR DNA; DNA; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PLACEBO; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA; MESSENGER RNA; SMALL INTERFERING RNA; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CHIMPANZEE; CHRONIC HEPATITIS B; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; HEPATITIS B VIRUS; HUMAN; IMMUNOSURVEILLANCE; LONG TERM CARE; MALE; MINICHROMOSOME; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNAI THERAPEUTICS; SINGLE DRUG DOSE; STUDY DESIGN; TREATMENT RESPONSE; VIRUS DNA CELL DNA INTERACTION; VIRUS INHIBITION; VIRUS LOAD; ANIMAL; CLINICAL TRIAL; DRUG EFFECT; GENETICS; LIVER; METABOLISM; NUCLEOTIDE SEQUENCE; PAN TROGLODYTES; PATHOLOGY; POLYADENYLATION; RNA INTERFERENCE; VIROLOGY; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; DNA, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; PAN TROGLODYTES; POLYADENYLATION; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA, VIRAL; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 85030237448     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aan0241     Document Type: Article

References (39)

1. GBD 2013 Mortality and Causes of Death Collaborators, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 385, 117-171 (2015).
2. M.-F. Yuen, S. H. Ahn, D.-S. Chen, P.-J. Chen, G. M. Dusheiko, J.-L. Hou, W. C. Maddrey, M. Mizokami, W.-K. Seto, F. Zoulim, C.-L. Lai, Chronic hepatitis B virus infection: Disease revisit and management recommendations. J. Clin. Gastroenterol. 50, 286-294 (2016).
3. R. P. Beasley, L.-Y. Hwang, C.-C. Lin, C.-S. Chien, Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 318, 1129-1133 (1981).
4. C. T. Bock, S. Schwinn, S. Locarnini, J. Fyfe, M. P. Manns, C. Trautwein, H. Zentgraf, Structural organization of the hepatitis B virus minichromosome. J. Mol. Biol. 307, 183-196 (2001).
5. Z. Jiang, S. Jhunjhunwala, J. Liu, P. M. Haverty, M. I. Kennemer, Y. Guan, W. Lee, P. Carnevali, J. Stinson, S. Johnson, J. Diao, S. Yeung, A. Jubb, W. Ye, T. D. Wu, S. B. Kapadia, F. J. de Sauvage, R. C. Gentleman, H. M. Stern, S. Seshagiri, K. P. Pant, Z. Modrusan, D. G. Ballinger, Z. Zhang, The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res. 22, 593-601 (2012).
6. V. Schlöter, M. Meyer, P. H. Hofschneider, R. Koshy, W. H. Caselmann, Integrated hepatitis B virus X and 3? truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene 9, 3335-3344 (1994).
7. M. J. F. Fowler, C. Greenfield, C.-M. Chu, P. Karayiannis, A. Dunk, A. S. F. Lok, C. L. Lai, E. K. Yeoh, J. P. Monjardino, B. M. Wankya, H. C. Thomas, Integration of HBV-DNA may not be a prerequisite for the maintenance of the state of malignant transformation. An analysis of 110 liver biopsies. J. Hepatol. 2, 218-229 (1986).
8. D. K.-H. Wong, M.-F. Yuen, H. Yuan, S. S.-M. Sum, C.-K. Hui, J. Hall, C.-L. Lai, Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 40, 727-737 (2004).
9. S. Staprans, D. D. Loeb, D. Ganem, Mutations affecting hepadnavirus plus-strand DNA synthesis dissociate primer cleavage from translocation and reveal the origin of linear viral DNA. J. Virol. 65, 1255-1262 (1991).
10. K. Kakimi, M. Isogawa, J. Chung, A. Sette, F. V. Chisari, Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: Implications for immunotherapy of persistent viral infections. J. Virol. 76, 8609-8620 (2002).
11. M. T. Chen, J.-N. Billaud, M. Sällberg, L. G. Guidotti, F. V. Chisari, J. Jones, J. Hughes, D. R. Milich, A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc. Natl. Acad. Sci. U.S.A. 101, 14913-14918 (2004).
12. D. R. Milich, J. E. Jones, J. L. Hughes, J. Price, A. K. Raney, A. McLachlan, Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc. Natl. Acad. Sci. U.S.A. 87, 6599-6603 (1990).
13. C. Boni, P. Fisicaro, C. Valdatta, B. Amadei, P. Di Vincenzo, T. Giuberti, D. Laccabue, A. Zerbini, A. Cavalli, G. Missale, A. Bertoletti, C. Ferrari, Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81, 4215-4225 (2007).
14. S. F. Wieland, F. V. Chisari, Stealth and cunning: Hepatitis B and hepatitis C viruses. J. Virol. 79, 9369-9380 (2005).
15. A. Bertoletti, C. Ferrari, Innate and adaptive immune responses in chronic hepatitis B virus infections: Towards restoration of immune control of viral infection. Gut 61, 1754-1764 (2012).
16. C. Seeger, F. Zoulim, W. S. Mason, Hepadnaviruses, in Fields Virology, B. N. Fields, D. M. Knipe, P. M. Howley, Eds. (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2007), chap. 76, pp. 2977-3030.
17. G.-A. Kim, Y.-S. Lim, J. An, D. Lee, J. H. Shim, K. M. Kim, H. C. Lee, Y.-H. Chung, Y. S. Lee, D. J. Suh, HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: Clinical outcomes and durability. Gut 63, 1325-1332 (2014).
18. M.-F. Yuen, D. K.-H. Wong, J. Fung, P. Ip, D. But, I. Hung, K. Lau, J. C.-H. Yuen, C.-L. Lai, HBsAg Seroclearance in chronic hepatitis B in Asian patients: Replicative level and risk of hepatocellular carcinoma. Gastroenterology 135, 1192-1199 (2008).
19. H. L.-Y. Chan, V. W.-S. Wong, G. L.-H. Wong, C.-H. Tse, H.-Y. Chan, J. J.-Y. Sung, A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 52, 1232-1241 (2010).
20. T. Schluep, J. Lickliter, J. Hamilton, D. L. Lewis, C.-L. Lai, J. Y. N. Lau, S. A. Locarnini, R. G. Gish, B. D. Given, Safety, tolerability, and pharmacokinetics of ARC-520 injection, an RNA interference-based therapeutic for the treatment of chronic hepatitis B Virus infection, in healthy volunteers. Clin. Pharmacol. Drug Dev. 6, 350-362 (2017).
21. C. I. Wooddell, D. B. Rozema, M. Hossbach, M. John, H. L. Hamilton, Q. Chu, J. O. Hegge, J. J. Klein, D. H. Wakefield, C. E. Oropeza, J. Deckert, I. Roehl, K. Jahn-Hofmann, P. Hadwiger, H.-P. Vornlocher, A. McLachlan, D. L. Lewis, Hepatocyte-Targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther. 21, 973-985 (2013).
22. T. Tu, W. S. Mason, A. D. Clouston, N. A. Shackel, G. W. McCaughan, M. M. Yeh, E. R. Schiff, A. R. Ruszkiewicz, J. W. Chen, H. A. J. Harley, U. H. Stroeher, A. R. Jilbert, Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection. J. Viral Hepat. 22, 737-753 (2015).
23. W. S. Mason, H.-C. Low, C. Xu, C. E. Aldrich, C. A. Scougall, A. Grosse, A. Clouston, D. Chavez, S. Litwin, S. Peri, A. R. Jilbert, R. E. Lanford, Detection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection. J. Virol. 83, 8396-8408 (2009).
24. Z. Wang, M. Gerstein, M. Snyder, RNA-Seq: A revolutionary tool for transcriptomics. Nat. Rev. Genet. 10, 57-63 (2009).
25. C. Hilger, I. Velhagen, H. Zentgraf, C. H. Schröder, Diversity of hepatitis B virus X generelated transcripts in hepatocellular carcinoma: A novel polyadenylation site on viral DNA. J. Virol. 65, 4284-4291 (1991).
26. F. van Bömmel, A. Bartens, A. Mysickova, J. Hofmann, D. H. Kröger, T. Berg, A. Edelmann, Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 61, 66-76 (2015).
27. Q. Su, S.-F. Wang, T.-E. Chang, R. Breitkreutz, H. Hennig, K. Takegoshi, L. Edler, C. H. Schröder, Circulating hepatitis B virus nucleic acids in chronic infection: Representation of differently polyadenylated viral transcripts during progression to nonreplicative stages. Clin. Cancer Res. 7, 2005-2015 (2001).
28. M. Martinot-Peignoux, T. Asselah, P. Marcellin, HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients. Liver Int. 35 (suppl. 1), 82-90 (2015).
29. W. S. Mason, C. Liu, C. E. Aldrich, S. Litwin, M. M. Yeh, Clonal expansion of normal-Appearing human hepatocytes during chronic hepatitis B virus infection. J. Virol. 84, 8308-8315 (2010).
30. S. J. Hadziyannis, H. M. Lieberman, G. G. Karvountzis, D. A. Shafritz, Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBcAg vs. anti-HBe positive carriers of hepatitis B virus. Hepatology 3, 656-662 (1983).
31. N. V. Naoumov, B. C. Portmann, R. S. Tedder, B. Ferns, A. L. W. F. Eddleston, G. J. M. Alexander, R. Williams, Detection of hepatitis B virus antigens in liver tissue. A relation to viral replication and histology in chronic hepatitis B infection. Gastroenterology 99, 1248-1253 (1990).
32. I.-J. Su, M.-Y. Lai, H.-C. Hsu, D.-S. Chen, P.-M. Yang, S.-M. Chuang, J.-L. Sung, Diverse virological, histopathological and prognostic implications of seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. J. Hepatol. 3, 182-189 (1986).
33. S. Asabe, S. F. Wieland, P. K. Chattopadhyay, M. Roederer, R. E. Engle, R. H. Purcell, F. V. Chisari, The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J. Virol. 83, 9652-9662 (2009).
34. H. L.-Y. Chan, V. W.-S. Wong, A. M.-L. Tse, C.-H. Tse, A. M.-L. Chim, H.-Y. Chan, G. L.-H. Wong, J. J.-Y. Sung, Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin. Gastroenterol. Hepatol. 5, 1462-1468 (2007).
35. A. J. V. Thompson, T. Nguyen, D. Iser, A. Ayres, K. Jackson, M. Littlejohn, J. Slavin, S. Bowden, E. J. Gane, W. Abbott, G. K. K. Lau, S. R. Lewin, K. Visvanathan, P. V. Desmond, S. A. Locarnini, Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51, 1933-1944 (2010).
36. V. K. Karra, S. J. Chowdhury, R. Ruttala, S. K. Polipalli, P. Kar, Clinical significance of quantitative HBsAg titres and its correlation with HBV DNA levels in the natural history of hepatitis B virus infection. J. Clin. Exp. Hepatol. 6, 209-215 (2016).
37. C.-L. Lai, D. Wong, P. Ip, M. Kopaniszen, W.-K. Seto, J. Fung, F.-Y. Huang, B. Lee, G. Cullaro, C. K. Chong, R. Wu, C. Cheng, J. Yuen, V. Ngai, M.-F. Yuen, Reduction of covalently closed circular DNA with long-Term nucleos(t)ide analogue treatment in chronic hepatitis B. J. Hepatol. 66, 275-281 (2017).
38. J. Petersen, V. Ratziu, M. Buti, H. L. A. Janssen, A. Brown, P. Lampertico, J. Schollmeyer, F. Zoulim, H. Wedemeyer, M. Sterneck, T. Berg, C. Sarrazin, M. Lutgehetmann, P. Buggisch, Entecavir plus tenofovir combination as rescue therapy in pre-Treated chronic hepatitis B patients: An international multicenter cohort study. J. Hepatol. 56, 520-526 (2012).
39. G. Sommer, T. Heise, Posttranscriptional control of HBV gene expression. Front. Biosci. 13, 5533-5547 (2008).